Recent Finacing
Recent Raise
Grin Therapeutics develops radiprodil, a selective GluN2B NMDA receptor modulator for rare neurodevelopmental disorders, entering pivotal Phase 3 for GRIN‑NDD and collaborating with Angelini for ex‑North America rights.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
